Quantcast
Home > Quotes > VVUS
VVUS

VIVUS, Inc. Common Stock (VVUS) Quote & Summary Data

$0.7302
*  
0.0023
0.31%
Get VVUS Alerts
*Delayed - data as of Jun. 25, 2018 14:02 ET  -  Find a broker to begin trading VVUS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VVUS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.7303 / $ 0.733
1 Year Target
1.5
Today's High / Low
$ 0.758 / $ 0.7101
Share Volume
378,471
50 Day Avg. Daily Volume
1,615,709
Previous Close
$ 0.7325
52 Week High / Low
$ 1.32 / $ 0.333
Market Cap
77,440,699
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.39
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.7

Intraday Chart

Shares Traded

Share Volume:
378,471
50 Day Avg. Daily Volume:
1,615,709

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.39

Trading Range

The current last sale of $0.7302 is 119.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.758 $ 1.32
 Low: $ 0.7101 $ 0.333

Company Description (as filed with the SEC)

VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs in human health. We have two approved therapies and one product candidate in active clinical development. Qsymia® (phentermine and topiramate extended release) is approved by FDA for chronic weight management. STENDRA® (avanafil) is approved for erectile dysfunction, or ED, by FDA and by the EC under the trade name SPEDRA in the EU. Tacrolimus is in active clinical development for the treatment of patients with pulmonary arterial hypertension, or PAH. Business Strategy Review In 2016, we initiated a business strategy review to maximize long-term stockholder value.  ... More ...  

Risk Grade

Where does VVUS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.742
Open Date:
Jun. 25, 2018
Close Price:
$ 0.7325
Close Date:
Jun. 22, 2018

Consensus Recommendation

Analyst Info